[News] UK–BioNTech partnership for mRNA cancer vaccines

The UK Government has signed a long-term partnership agreement with the German company BioNTech to support clinical trials for personalised mRNA cancer immunotherapies. This partnership could mean access to precision cancer treatment for up to 10 000 patients in the UK by 2030 and includes plans for new facilities and staff to support the initiative.